Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Classically, the response assessment to systemic treatment is based on RECIST. In PNET treated with antiangiogenic targeted therapy as sunitinib there is no good correlation between response rate and progression free survival (PFS). Choi criteria might be an alternative to RECIST to evaluate the effect of sunitinib in patients with advanced PNET
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author: Solis Hernandez P
Authors: Solis Hernandez M, Calvo-Temprano D, Jiménez-Fonseca P, Faez L, Ruiz A,
Introduction: Phase III trials of sunitinib, everolimus and octreotide lar confirmed that these drugs improved progression-free survival (PFS) in well-differentiated PNET, low/intermediate grade pNET and well-differentiated midgut NETs, respectively. CLARINET is the 1st phase III study that showed PFS benefit of SSA, lanreotide, in both P- and midgut NET and in Ki-67 5-10%.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author:
Authors: Jiménez-Fonseca P, Carmona A, Faez L, Solis P, Rodriguez D,
Keywords: Ki-67, pancreatic neuroendocrine tumor, systemic therapy,
Introduction: Sunitinib and everolimus were approved for treatment of progressive PNET based on phase III trial data. However, features that may influence outcome with these antitargets have not been well-established.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author:
Authors: Jiménez-Fonseca P, Carmona A, Solis M, Faez L, Ruiz A,
Keywords: Sunitinib, pancreatic neuroendocrine tumor, prior treatment, predictive factor,
#642 Correlation Between Chromogranin A and RECIST in Neuroendocrine Tumors’ Treatment
Introduction: High Chromogranin A (CGA) levels have been associated with both tumor burden and the secretory activity of GEPNETs specially carcinoids.
Conference: 10th Annual ENETSConcerence (2013)
Presenting Author: Fonseca P
Authors: Solís M, Fonseca P, Uriol E, Faez L, Pérez Q,
Keywords: Chromogranin A, response, RECIST, predictive values,
Introduction: GEP-NETs are malignant entities poorly understood still, deserving important attention for a better management of the disease.
Conference: 10th Annual ENETSConcerence (2013)
Presenting Author: Solís M
Authors: Solís M, Fonseca P, Faez L, Álvarez C, Pérez Q,
Keywords: metastatic, GEP-NETs, clinical practice, markers, surgery, chemotherapy,